Medication info

Rocarb Tablet 120/20 mg

Prescription medicationTabletOral
Ingredient · strength
Fimasartan Potassium Trihydrate Granules›300mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Boryung Biopharma Co., Ltd.
Appearance
Orange oval film-coated tablets
Packaging
30 tablets (10 tablets/PTP packaging x 3), 100 tablets (10 tablets/PTP packaging x 10)
Approval status
Active

MFDS item code 201700493 · Approved 2017.01.25

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, reduction of cardiovascular disease risk and inhibition of atherosclerosis progression
Who takes it
Adults
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, fimasartan/rosuvastatin. ○ Fimasartan 1. Adults The recommended dose is 30~60 milligrams once daily, administered regardless of food. If blood pressure is not adequately controlled at this dose, it may be increased to 120 milligrams once daily. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect after approximately 8 weeks~12 weeks. 2. Older adults No initial dosage adjustment is required for older adults up to 70 years of age. (See section 9, Administration to Older Adults, under Precautions for Use.) 3. Patients with renal impairment No dosage adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30~80 mL/min). In patients with severe renal impairment (creatinine clearance < 30 mL/min), initiate treatment at 30 milligrams once daily and do not exceed 60 milligrams daily. 4. Patients with hepatic impairment No dosage adjustment is required in patients with mild hepatic impairment. Do not administer this medicine to patients with moderate to severe hepatic impairment (see section 2, Patients in Whom the Medicine Must Not Be Administered, and section 10, Administration to Patients with Hepatic Impairment, under Precautions for Use). 5. Patients with reduced effective circulating blood volume (e.g., patients taking high doses of diuretics) For patients at high risk of hypotension, such as those with reduced effective circulating blood volume, an initial dose of 30 milligrams once daily is recommended. (See section 3, Administration with Caution, under Precautions for Use.) ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, adjust the dose to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Older adults No dosage adjustment is required. 3. Patients with renal failure No dosage adjustment is required in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Use particular caution when administering 20mg of this medicine to patients with moderate renal failure. 4. Patients with hepatic failure No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking fimasartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination containing the same amounts of each active ingredient) for convenience.

Ingredients

Manufacturer
Boryung Biopharma Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, reduction of cardiovascular disease risk and inhibition of atherosclerosis progression

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • dysbetalipoproteinemia
  • hypercholesterolemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is used for patients who require administration of both Pemasartan and Rosuvastatin. Pemasartan helps to control blood pressure in patients with essential hypertension. Rosuvastatin is used as an adjunct therapy to lower cholesterol levels in patients with hypercholesterolemia who are not adequately controlled with diet. It also assists in the treatment of patients with homozygous familial hypercholesterolemia and dysbetalipoproteinemia. For patients at high risk of cardiovascular disease, it helps to reduce the risk of cardiovascular events such as stroke and myocardial infarction. In summary, this medication is used in combination for hypertension, hyperlipidemia, and reduction of cardiovascular disease risk.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, fimasartan/rosuvastatin. ○ Fimasartan 1. Adults The recommended dose is 30~60 milligrams once daily, administered regardless of food. If blood pressure is not adequately controlled at this dose, it may be increased to 120 milligrams once daily. If possible, it is recommended to take the medicine at the same time each day (e.g., in the morning). The antihypertensive effect appears within 2 weeks after starting treatment and reaches its maximum effect after approximately 8 weeks~12 weeks. 2. Older adults No initial dosage adjustment is required for older adults up to 70 years of age. (See section 9, Administration to Older Adults, under Precautions for Use.) 3. Patients with renal impairment No dosage adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30~80 mL/min). In patients with severe renal impairment (creatinine clearance < 30 mL/min), initiate treatment at 30 milligrams once daily and do not exceed 60 milligrams daily. 4. Patients with hepatic impairment No dosage adjustment is required in patients with mild hepatic impairment. Do not administer this medicine to patients with moderate to severe hepatic impairment (see section 2, Patients in Whom the Medicine Must Not Be Administered, and section 10, Administration to Patients with Hepatic Impairment, under Precautions for Use). 5. Patients with reduced effective circulating blood volume (e.g., patients taking high doses of diuretics) For patients at high risk of hypotension, such as those with reduced effective circulating blood volume, an initial dose of 30 milligrams once daily is recommended. (See section 3, Administration with Caution, under Precautions for Use.) ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily; if a greater reduction in LDL cholesterol is required, adjust the dose to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. Adjust the maintenance dose as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; it may be increased to a maximum of 20 milligrams daily. 2. Older adults No dosage adjustment is required. 3. Patients with renal failure No dosage adjustment is required in patients with mild or moderate renal failure. Do not administer to patients with severe renal failure. Use particular caution when administering 20mg of this medicine to patients with moderate renal failure. 4. Patients with hepatic failure No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking fimasartan and rosuvastatin concomitantly may switch to this medicine (a fixed-dose combination containing the same amounts of each active ingredient) for convenience.

Precautions

This medication can cause severe harm to the fetus and newborn if taken during pregnancy, especially during the second and third trimesters, therefore it should be discontinued immediately upon confirmation of pregnancy. Patients allergic to any of the ingredients in this drug, pregnant or potentially pregnant women, and breastfeeding women should not take this medication. Patients with severely decreased liver function, very poor kidney function, or specific muscle diseases should also avoid this medication. Patients with low blood volume or sodium levels need to carefully monitor their condition at the onset of treatment with this medication, as blood pressure may drop too low. Patients with impaired kidney function, renal artery hypertension, or heart disease require special caution when taking this medication. If symptoms such as muscle pain or weakness occur, consult a doctor immediately; in severe cases, the medication should be discontinued. It is recommended that regular liver function tests and blood tests be performed during treatment with this medication. Interactions may occur when taking this medication with other drugs, so it is essential to inform the doctor or pharmacist of all medications currently being taken. Pregnant or breastfeeding women should not take this medication, and women of childbearing age should use appropriate contraception. Safety in children and adolescents under 18 years has not been established, so caution is needed in such use. Elderly patients may be more sensitive to this medication, so dose adjustments and monitoring may be necessary. In cases of overdose, symptoms such as hypotension or heart rhythm abnormalities may occur; immediate medical attention should be sought for proper treatment. Dizziness may occur during driving or operating machinery while taking this medication, so caution is advised. Keep this medication out of the reach of children and do not transfer it to other containers.

Side effects

Dyspepsia, nausea, fever, hepatitis, headache, dizziness, upper abdominal pain, esophagitis, gastritis, nasopharyngitis, tonsillitis, upper respiratory tract infection, elevated ALT, elevated γ-GTP, increased liver enzyme levels, increased white blood cell count, urinary dysfunction, frequent urination, cough, hyperkalemia, arthralgia, insomnia, pruritus, syncope, sedation, migraine, vomiting, weakness, foreign body sensation, reduced platelet count, increased serum creatine phosphokinase, muscle contraction, musculoskeletal rigidity, facial flushing, flushing, erectile dysfunction, angioedema, hypersensitivity reactions, constipation, abdominal pain, pancreatitis, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, jaundice, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, nightmares, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscular weakness, ocular myasthenia, contusion, epilepsy, amyotrophic lateral sclerosis, neuropathy, neuronitis, facial paralysis, normal pressure hydrocephalus, spinal canal stenosis, acute pancreatitis, intestinal obstruction, hemorrhagic duodenal ulcer, appendicitis, hemorrhoids, abdominal pain, intracranial hemorrhage, transient ischemic attack, atherosclerosis, worsening cerebral infarction, cerebral hemorrhage, liver cancer, colorectal carcinoma, neoplasm of unspecified nature, cervical cancer, prostate cancer, acute renal failure, chronic renal failure, kidney stones, pyelonephritis, incontinence, rhinitis, fibrosing alveolitis, pharyngitis, pneumonia, lung disease, death, worsening back pain, osteoarthritis, arthrosis, hypoglycemia, pulmonary embolism, purpura, bradycardia, atrial fibrillation, coronary artery disease, aortic stenosis, heart failure, elevated blood pressure, acute hepatitis, benign pituitary neoplasm, otitis media, uterine prolapse, recurrent cancer, chest pain, back pain, edema, limb pain, peripheral edema, facial edema, fatigue, fever, neck/shoulder pain, fracture, arthralgia, osteoporosis, myalgia, pharyngitis, upper respiratory tract infection, sputum, rhinitis, epistaxis, bronchitis, sensory disturbance, numbness, tremor, hypertonia, anxiety, memory disturbance, anorexia, gastroesophageal reflux, gastritis, diarrhea, functional gastrointestinal disorder, gastroenteritis, frequent urination, incontinence, kidney stones, chronic renal failure, dysuria, hyperlipidemia, dyslipidemia, hypoglycemia, elevated blood pressure, purpura, fatty liver, localized inflammation, soft tissue infection, lymphadenopathy, abrasion of unspecified nature, septal deviation, surgical intervention, postoperative pain, fever intolerance, fall, postoperative pain, chest discomfort, anorexia, abdominal distention, abnormal liver function test, generalized pain, muscle cramp, gout, erectile dysfunction, contusion

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, maintaining a storage temperature between 1 and 30 degrees Celsius. By storing it this way, the medication's effectiveness will be well maintained, preventing deterioration.

Appearance and packaging

Appearance

Orange oval film-coated tablets

Package unit

30 tablets (10 tablets/PTP packaging x 3), 100 tablets (10 tablets/PTP packaging x 10)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.